Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Neutral 0

Charles River Labs (CRL) Gets a Hold from Morgan Stanley

AI-generated analysis

🔍 Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Charles River Labs (CRL) with a price target of $168.46.

📉 TipRanks data indicates analyst Titchmarsh has an average return of -0.8% and a 34.29% success rate covering the Healthcare sector.

➕ Mizuho Securities’s Ann Hynes also issued a Hold rating on CRL in a report from May 8, adding to recent cautious sentiment.

🟢 Conversely, William Blair reiterated a Buy rating on Charles River Labs, offering a contrasting positive outlook to the other analysts.

💰 For the quarter ending March 28, Charles River reported revenue of $995.83 million, showing slight growth from $984.17 million last year.

📉 The company recorded a GAAP net loss of $14.84 million this quarter, down from a net profit of $25.47 million in the prior-year period.

🧪 Charles River operates within the Healthcare sector and focuses on services such as those offered by West Pharmaceutical Services and Stevanato Group.

📰 Related news mentions share approval for a new incentive plan and 'continued momentum' in its digital pathology platform.

📈 Other analysts, such as Evercore ISI, recently raised CRL's price target to $220, highlighting varying market opinions on the stock.

⚠️ Potential risks include cyber threats like AI-enabled attacks and third-party risks mentioned in recent coverage of the company.

Full Analysis
Morgan Stanley analyst Kallum Titchmarsh maintained a Hold rating on Charles River Laboratories (CRL) following the company's recent earnings release, setting a price target of $168.46. This action comes amidst mixed signals for the biopharmaceutical services company, as William Blair reiterated its Buy rating and Mizuho Securities also issued a Hold via analyst Ann Hynes on May 8. The article highlights that Charles River Labs reported quarterly revenue of $995.83 million for the quarter ending March 28, showing modest growth from last year's $984.17 million, but notably posted a GAAP net loss of $14.84 million compared to a net profit of $25.47 million in the same period prior year. Analyst Kallum Titchmarsh covers the healthcare sector and has historically maintained an average return of -0.8% with a 34.29% success rate according to TipRanks data. The report serves as an update on the shifting analyst sentiment regarding Charles River Labs, contrasting the new Hold rating from Morgan Stanley with the continued optimism from William Blair which previously maintained a $235 price target.